|
| 35047909 | Multiple Sclerosis: LIFNano-CD4 for Trojan Horse Delivery of the Neuro-Protective Biologic "LIF" Into the Brain: Preclinical Proof of Concept. | Front Med Technol | 2021 |
| 32296777 | Mesenchymal stem cells and management of COVID-19 pneumonia. | Med Drug Discov | 2020 |
| 32681950 | Delivering the power of nanomedicine to patients today. | J Control Release | 2020 |
| 29448112 | LIF and multiple sclerosis: One protein with two healing properties. | Mult Scler Relat Disord | 2018 |
| 27924726 | Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy. | Curr Pharm Des | 2017 |
| 25303042 | Stem cell therapy versus T lymphocytes: friend or foe? | Stem Cells | 2015 |
| 29942371 | Multiple Sclerosis and the LIF/IL-6 Axis: Use of Nanotechnology to Harness the Tolerogenic and Reparative Properties of LIF. | Nanobiomedicine (Rij) | 2015 |
| 25934281 | Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF). | Biomaterials | 2015 |
| 24821983 | The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro. | Development | 2014 |
| 25085990 | Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease. | Dis Model Mech | 2014 |
| 22172276 | Targeted nanotherapy for induction of therapeutic immune responses. | Trends Mol Med | 2012 |
| 23227162 | Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice. | PLoS One | 2012 |
| 20977190 | Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. | Mol Pharm | 2011 |
| 21921909 | Multiple sclerosis: One protein, two healing properties. | Nature | 2011 |
| 21368774 | LIF in the regulation of T-cell fate and as a potential therapeutic. | Genes Immun | 2011 |
| 19901269 | The E3 ligase axotrophin/MARCH-7: protein expression profiling of human tissues reveals links to adult stem cells. | J Histochem Cytochem | 2010 |
| 20962578 | A LIF/Nanog axis is revealed in T lymphocytes that lack MARCH-7, a RINGv E3 ligase that regulates the LIF-receptor. | Cell Cycle | 2010 |
| 19342884 | Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. | Cell Cycle | 2009 |
| 18282245 | In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFbeta, but has no immediate effect on Foxp3. | Transpl Int | 2008 |
| 17632414 | Regulatory transplantation tolerance and "stemness": evidence that Foxp3 may play a regulatory role in SOCS-3 gene transcription. | Transplantation | 2007 |
| 17161353 | Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance. | Int Immunopharmacol | 2006 |
| 15670816 | Leukaemia inhibitory factor (LIF) is functionally linked to axotrophin and both LIF and axotrophin are linked to regulatory immune tolerance. | FEBS Lett | 2005 |
| 16147533 | Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance. | Philos Trans R Soc Lond B Biol Sci | 2005 |
| 16147527 | Introduction: immunoregulation: harnessing T cell biology for therapeutic benefit. | Philos Trans R Soc Lond B Biol Sci | 2005 |
| 15589457 | Transplantation tolerance: gene expression profiles comparing allotolerance vs. allorejection. | Int Immunopharmacol | 2005 |
| 15785381 | Leukemia inhibitory factor is linked to regulatory transplantation tolerance. | Transplantation | 2005 |
| 15185378 | New rapamycin derivatives by precursor-directed biosynthesis. | Chembiochem | 2004 |
| 11821948 | The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. | Oncogene | 2002 |
| 12355453 | Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. | Eur J Immunol | 2002 |
| 12121281 | The interleukin-1 receptor antagonist gene: a single-copy variant of the intron 2 variable number tandem repeat (VNTR) polymorphism. | Eur J Immunogenet | 2002 |
| 11267421 | Genetic modulators of interleukin 1 activity influence the development of chronic rejection in human thoracic allografts. | Transplant Proc | 2001 |
| 10798785 | STAT 6 up-regulation by FK506 in the presence of interleukin-4. | Transplantation | 2000 |
| 10836388 | Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. | Transplantation | 2000 |
| 11056691 | P53 autoantibodies in 1006 patients followed up for breast cancer. | Breast Cancer Res | 2000 |
| 11156359 | An ex vivo model of tolerance vs. rejection: comparison of different signal transducers and activators of transcription, STAT1, STAT4, STAT5 and STAT6. | Clin Chem Lab Med | 2000 |
| 11112057 | Allo-tolerance and allorejection responses ex vivo. | Transpl Int | 2000 |
| 10597303 | A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein. | Oncogene | 1999 |
| 10342309 | Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. | Transplantation | 1999 |
| 10327055 | Wild-type p53 protein shows calcium-dependent binding to F-actin. | Oncogene | 1999 |
| 10083346 | Thymic-independent peripheral tolerance. | Transplant Proc | 1999 |
| 10500655 | Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. | Transplant Proc | 1999 |
| 10496344 | Proteolytic cleavage of p53 mutants in response to mismatched DNA. | Br J Cancer | 1999 |
| 10578277 | Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies. | Transplant Proc | 1999 |
| 10578271 | FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. | Transplant Proc | 1999 |
| 10480422 | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | Transplantation | 1999 |
| 9745493 | Tolerance induction with peripheral blood lymphocyte depletion using monoclonal antibodies: tip of the iceberg? | Transplant Proc | 1998 |
| 9473033 | Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase. | J Bacteriol | 1998 |
| 9865315 | In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. | Transplant Proc | 1998 |
| 9865297 | Comparative efficacy of liposomal FK506 with FK506. | Transplant Proc | 1998 |
| 9349496 | Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. | Oncogene | 1997 |